Bristol Myers (BMY)’ treatment of small cell lung cancer, atigotatug plus nivolumab fixed dose combination, received FDA orphan designation, ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

The study enrolled 64 patients with treatment-naïve metastatic melanoma between March 2017 and July 2019. Participants ...

nivolumab plus ipilimumab and nivolumab plus relatlimab. Both immunotherapy combinations appeared to perform equally well.

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.

FLuID enables privacy-preserving knowledge sharing in drug discovery using knowledge distillation. The results show that the approach expands applicability domains and fosters collaboration across ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus ...